|

ProAgio Dose Expansion Clinical Trials

1 actively recruiting trial across 1 location

Also known as: ACT50, Gemcitabine

Pipeline

Phase 1/2: 1

Top Sponsors

  • ProDa BioTech, LLC1

Indications

  • Triple Negative Breast Cancer1
  • Breast Cancer1
  • Cancer1

Atlanta, Georgia1 trial

ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Emory University Winship Cancer Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.